title: BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
authors.forename: Jurgen
authors.initials: J
authors.lastname: Veeck
authors.forename: Santiago
authors.initials: S
authors.lastname: Ropero
authors.forename: Fernando
authors.initials: F
authors.lastname: Setien
authors.forename: Eva
authors.initials: E
authors.lastname: Gonzalez-Suarez
authors.forename: Ana
authors.initials: A
authors.lastname: Osorio
authors.forename: Javier
authors.initials: J
authors.lastname: Benitez
authors.forename: James G
authors.initials: JG
authors.lastname: Herman
authors.forename: Manel
authors.initials: M
authors.lastname: Esteller
mesh_terms: D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D018899:CpG Islands / Q000235:genetics*; D019175:DNA Methylation; D005260:Female; D018095:Germ-Line Mutation; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D010793:Phthalazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000235:genetics; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D019313:BRCA1 Protein; D024682:BRCA2 Protein; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases; C531550:olaparib